Fracture Risk Prediction in Patients with Inflammatory Arthritis Using Combined Clinical, Densitometric, and Endocrine Biomarkers
Development and Validation of a Risk Score
Patients with inflammatory arthritis face elevated fracture risk. Chronic inflammation, glucocorticoid use, and reduced physical activity weaken bone. Standard tools such as FRAX often underestimate this risk. Therefore, improved prediction models remain necessary.
This study develops and validates a fracture risk score. The model combines clinical, densitometric, and endocrine biomarkers. It targets adults with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
Clinical variables include age, sex, disease duration, cumulative glucocorticoid dose, prior fracture history, and disease activity scores. Densitometric measures capture bone mineral density at the lumbar spine and femoral neck. Endocrine biomarkers add further information. These include serum 25-hydroxyvitamin D, parathyroid hormone, bone turnover markers, and morning cortisol levels where relevant.
Researchers will construct the score in a derivation cohort. They will apply multivariable logistic regression and survival analysis. Variable selection will balance statistical performance with clinical practicality. The resulting points-based or equation-based score will estimate absolute fracture risk over five and ten years.
External validation will follow in an independent cohort. Analysts will assess discrimination using the C-statistic and calibration with observed-versus-predicted plots. Reclassification indices will compare the new score against FRAX alone. Sensitivity analyses will examine performance across arthritis subtypes and glucocorticoid exposure levels.
Several advantages support this combined approach.
Clinical factors reflect disease burden and treatment effects. Densitometry quantifies current bone mass. Endocrine markers capture metabolic influences on bone remodeling. Together, these domains provide a more complete risk profile.
The final risk score aims to guide clinical decisions.
Physicians can identify high-risk patients earlier. They can then intensify bone-protective strategies. Moreover, the model may support more rational use of anti-osteoporotic therapies in rheumatology practice.
The research design emphasizes transparency and reproducibility. Clear reporting of derivation and validation steps will strengthen confidence in the results. Future studies can test the score in additional populations or incorporate genetic markers. For now, the focus remains on developing and validating a practical tool that integrates clinical, densitometric, and endocrine data for fracture risk prediction in inflammatory arthritis.